Michael Dempsey
Endocrinology, Diabetes & Metabolism · Rockville, MDNPI 1730197229
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $3,170 of the $4,493 with a category attached, or 70.5%. Eli Lilly accounts for 89.5% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2019 at $2,839 and has fallen 96.1% since, to $112 in 2022.
Across 33 payments — averaging $136.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$4K
- Sanofi-aventis U.S. LLC$350
- Dexcom, Inc.$112
- Lilly USA, LLC$8
Across 1,295 payments — averaging $2148.30 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$2M
- Novo Nordisk AS$345K
- Sanofi US Services Inc.$225K
- Medtronic$162K
- Sanofi-aventis U.S. LLC$4K
What the payments were for
- Speaking & faculty fees$3508%
- Travel & lodging$3,17071%
- Food & beverage$96521%
- Education$80%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 30 | $4,023 |
| Sanofi-aventis U.S. LLC | 1 | $350 |
| Dexcom, Inc. | 1 | $112 |
| Lilly USA, LLC | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,493 in reported general payments places this provider in the 70th percentile of 235 endocrinology, diabetes & metabolism providers in Maryland.
See all endocrinology, diabetes & metabolism providers in Maryland →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 141 | $258,081 |
| JardianceEmpagliflozin | 125 | $167,052 |
| MounjaroTirzepatide | 84 | $99,336 |
| TrulicityDulaglutide | 30 | $54,116 |
| Tresiba Flextouch U-200Insulin Degludec | 40 | $47,169 |
| Tresiba Flextouch U-100Insulin Degludec | 51 | $37,812 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 38 | $37,503 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 18 | $17,295 |
| SynthroidLevothyroxine Sodium | 148 | $16,378 |
| Lyumjev Kwikpen U-100Insulin Lispro-Aabc | 14 | $13,180 |
| NovologInsulin Aspart | 27 | $10,413 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 11 | $8,374 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 58 | $7,277 |
| Humalog Kwikpen U-100Insulin Lispro | 18 | $5,925 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 27 | $4,260 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $8 | $153,453114 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 235 endocrinology, diabetes & metabolism providers in Maryland.
Other endocrinology, diabetes & metabolism in Rockville
- David BrownRockville$497K
- Helena RodbardRockville$468K
- Gerti TashkoRockville$106K
- Jie HeRockville$26K
- Monika MannanRockville$8K
- Daniel GozziSuitland$1.2M
- Martin SarkarFrederick$1.1M
- Nicholas ArgentoLaurel$1.1M
- Romeu AzevedoCamp Springs$987K
- Philip LevinBaltimore$489K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.